Small-molecule inhibition of TLR8 through stabilization of its resting state

Nature Chemical Biology

Volumn 14, Issue 1, 2018, Pages 58-64

  Zhang, Shuting ^a,b,c   Hu, Zhenyi ^b   Tanji, Hiromi ^d   Jiang, Shuangshuang ^a   Das, Nabanita ^b   Li, Jing ^e   Sakaniwa, Kentaro ^d   Jin, Jin ^f   Bian, Yanyan ^f   Ohto, Umeharu ^d   Shimizu, Toshiyuki ^d   Yin, Hang ^a,b  

^a TSINGHUA UNIVERSITY   (China)

^b UNIVERSITY OF COLORADO   (United States)

^c HENAN NORMAL UNIVERSITY   (China)

^d UNIVERSITY OF TOKYO   (Japan)

^e PEKING UNION MEDICAL COLLEGE   (China)

^f PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HOMODIMER; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR ANTAGONIST; LIGAND; TLR8 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MOLECULAR LIBRARY; MOLECULAR MODEL; MONONUCLEAR CELL; PHARMACOLOGY; PROTEIN MULTIMERIZATION; RHEUMATOID ARTHRITIS; SYNOVIUM;

ARTHRITIS, RHEUMATOID; BINDING SITES; CELL LINE; CELL PROLIFERATION; HUMANS; IMMUNITY, INNATE; LEUKOCYTES, MONONUCLEAR; LIGANDS; MODELS, MOLECULAR; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; SMALL MOLECULE LIBRARIES; SYNOVIAL MEMBRANE; TOLL-LIKE RECEPTOR 8; TRANSFECTION;

EID: 85037718799     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2518     Document Type: Article

References (56)

1. Mogensen, T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240-273 (2009).
2. Broz, P. & Monack, D.M. Newly described pattern recognition receptors team up against intracellular pathogens. Nat. Rev. Immunol. 13, 551-565 (2013).
3. Pasare, C. & Medzhitov, R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect. 6, 1382-1387 (2004).
4. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
5. Kawai, T. & Akira, S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol. Med. 13, 460-469 (2007).
6. Carpenter, S. & ONeill, L.A. How important are Toll-like receptors for antimicrobial responses? Cell. Microbiol. 9, 1891-1901 (2007).
7. Kanzler, H., Barrat, F.J., Hessel, E.M. & Coffman, R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13, 552-559 (2007).
8. Mohammad Hosseini, A., Majidi, J., Baradaran, B. & Yousefi, M. Toll-like receptors in the pathogenesis of autoimmune diseases. Adv. Pharm. Bull. 5 Suppl 1: 605-614 (2015).
9. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004).
10. Panter, G., Kuznik, A. & Jerala, R. Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr. Opin. Mol. Ther. 11, 133-145 (2009).
11. Gantier, M.P. et al. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J. Immunol. 180, 2117-2124 (2008).
12. Gorden, K.B. et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174, 1259-1268 (2005).
13. Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526-1529 (2004).
14. Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196-200 (2002).
15. Papadimitraki, E.D., Bertsias, G.K. & Boumpas, D.T. Toll like receptors and autoimmunity: A critical appraisal. J. Autoimmun. 29, 310-318 (2007).
16. Barrat, F.J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131-1139 (2005).
17. Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823-835 (2006).
18. Watanabe, M. et al. Dihydropyrrolo[2, 3-d]pyrimidines: selective toll-like receptor 9 antagonists from scaffold morphing efforts. ACS Med. Chem. Lett. 5, 1235-1239 (2014).
19. Cheng, K., Wang, X. & Yin, H. Small-molecule inhibitors of the TLR3/dsRNA complex. J. Am. Chem. Soc. 133, 3764-3767 (2011).
20. Hennessy, E.J., Parker, A.E. & ONeill, L.A. Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug Discov. 9, 293-307 (2010).
21. Kondo, T., Kawai, T. & Akira, S. Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol. 33, 449-458 (2012).
22. Botos, I., Segal, D.M. & Davies, D.R. The structural biology of Toll-like receptors. Structure 19, 447-459 (2011).
23. Tanji, H., Ohto, U., Shibata, T., Miyake, K. & Shimizu, T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science 339, 1426-1429 (2013).
24. Tanji, H. et al. Toll-like receptor 8 senses degradation products of singlestranded RNA. Nat. Struct. Mol. Biol. 22, 109-115 (2015).
25. Kokatla, H.P. et al. Exquisite selectivity for human toll-like receptor 8 in substituted furo[2, 3-c]quinolines. J. Med. Chem. 56, 6871-6885 (2013).
26. Salunke, D.B. et al. Structure-Activity relationships in human Toll-like receptor 8-Active 2, 3-diamino-furo[2, 3-c]pyridines. J. Med. Chem. 55, 8137-8151 (2012).
27. Kuznik, A. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186, 4794-4804 (2011).
28. Schön, M.P. & Schön, M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 27, 190-199 (2008).
29. Lamphier, M. et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol. Pharmacol. 85, 429-440 (2014).
30. Liu, H., Liu, Z.H., Chen, Z.H., Yang, J.W. & Li, L.S. Triptolide: A potent inhibitor of NF-kappa B in T-lymphocytes. Acta Pharmacol. Sin. 21, 782-786 (2000).
31. Jurk, M. et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3, 499 (2002).
32. Yin, H. & Flynn, A.D. Drugging membrane protein interactions. Annu. Rev. Biomed. Eng. 18, 51-76 (2016).
33. Beesu, M. et al. Structure-based design of human TLR8-specific agonists with augmented potency and adjuvanticity. J. Med. Chem. 58, 7833-7849 (2015).
34. Valencia Pacheco, G.J. et al. Expression and activation of intracellular receptors TLR7, TLR8 and TLR9 in peripheral blood monocytes from HIV-infected patients. Colomb. Med. 44, 92-99 (2013).
35. Zhang, Z. et al. Structural analysis reveals that toll-like receptor 7 Is a dual receptor for guanosine and single-stranded RNA. Immunity 45, 737-748 (2016).
36. Kaczanowska, S., Joseph, A.M. & Davila, E. TLR agonists: our best frenemy in cancer immunotherapy. J. Leukoc. Biol. 93, 847-863 (2013).
37. Doyle, S. et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 17, 251-263 (2002).
38. Tseng, P.H. et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat. Immunol. 11, 70-75 (2010).
39. Duffy, L. & OReilly, S.C. Toll-like receptors in the pathogenesis of autoimmune diseases: recent and emerging translational developments. ImmunoTargets Ther. 5, 69-80 (2016).
40. Liu, J. et al. A five-Amino-Acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol. Immunol. 47, 1083-1090 (2010).
41. Mullen, L., Ferdjani, J. & Sacre, S. Simvastatin inhibits Toll-like receptor 8 (TLR8) signaling in primary human monocytes and spontaneous tumor necrosis factor production from rheumatoid synovial membrane cultures. Mol. Med. 21, 726-734 (2015).
42. Sacre, S.M. et al. Inhibitors of TLR8 reduce TNF production from human rheumatoid synovial membrane cultures. J. Immunol. 181, 8002-8009 (2008).
43. Castañeda, S., Blanco, R. & González-Gay, M.A. Adult-onset Stills disease: Advances in the treatment. Best Pract. Res. Clin. Rheumatol. 30, 222-238 (2016).
44. Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145 (2001).
45. Piccinini, A.M. & Midwood, K.S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010, 672395 (2010).
46. Guiducci, C. et al. RNA recognition by human TLR8 can lead to autoimmune inflammation. J. Exp. Med. 210, 2903-2919 (2013).
47. Cheng, K. et al. Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists. Sci. Adv. 1, e1400139 (2015).
48. Csakai, A. et al. Saccharin derivatives as inhibitors of interferon-mediated inflammation. J. Med. Chem. 57, 5348-5355 (2014).
49. Das, N. et al. HMGB1 activates proinflammatory signaling via TLR5 leading to allodynia. Cell Rep. 17, 1128-1140 (2016).
50. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
51. Battye, T.G., Kontogiannis, L., Johnson, O., Powell, H.R. & Leslie, A.G. iMOSFLM: A new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271-281 (2011).
52. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22-25 (2010).
53. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
54. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
55. Brennan, F.M., Chantry, D., Jackson, A.M., Maini, R.N. & Feldmann, M. Cytokine production in culture by cells isolated from the synovial membrane. J. Autoimmun. 2 (Suppl.) 177-186 (1989).
56. Ulmer, A.J., Scholz, W., Ernst, M., Brandt, E. & Flad, H.D. Isolation and subfractionation of human peripheral blood mononuclear cells (PBMC) by density gradient centrifugation on Percoll. Immunobiology 166, 238-250 (1984).